Activated HIF-1α can promote glycolysis by regulating its downstream target proteins such as VEGF (promotes angiogenesis), GLUT1 (promotes glucose transport), LDHA (promotes glycolysis), etc. Whether roxadustat can play some positive therapeutic role in DM by regulating HIF-1α is an important aspect to develop and expand its clinical application. This evidence concerns the gene SLC2A1 and diabetes mellitus.